Q3 2025 GVS SpA Earnings Call Transcript
Key Points
- Healthcare and Life Science division experienced a growth of 4.8%, excluding FX impacts.
- Adjusted EBITDA margin improved to nearly 25%, showing a positive trend compared to the previous year.
- Safety division maintained a stable growth trajectory with an 8.5% increase, excluding FX impacts.
- The company completed the transfer of production machinery to its Mexico plant, enhancing operational independence.
- New hydrogen membrane production line is fully operational, with products being sent for customer validation.
- Energy Mobility division faced a significant decline with a 10.8% decrease in sales.
- Negative FX impacts resulted in a EUR6.9 million loss, affecting overall financial performance.
- US dialysis business experienced a volume loss of EUR7.9 million, continuing a negative trend.
- Net financial position showed a leverage ratio increase to 2.5, influenced by M&A and buyback activities.
- Working capital trends were negative, with a EUR20 million impact, though expected to recover by year-end.
Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the GVS nine Months 2025 Results Conference Call. At this time, I would like to turn the conference over to Mr. Massimo Scagliarini, CEO.Please go ahead, sir.
Thank you, very much. Good afternoon and good morning, and welcome to the nine months 2025 results presentation of the GVS Group. A quick snapshot on the main number. Healthcare and Life Science, a nice growth of 4.8%, excluding FX and the US dialysis and safety revenues plus 8.5% year-on-year, so nice speed of both division.
Adjusted EBITDA margin at nearly 25%, so plus 60 versus the nine months 2024. Adjusted net income net of FX at plus 7.2% versus the previous year to EUR36.3 million, increasing the margin to 11.5% from the 10.5% of the nine months 2024. Net financial position, EUR271 million as of September '25 with the leverage ratio post M&A at 2.5. Leverage ratio, 2025, excluding the extraordinary effect of M&A
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
